Evidence map›Paper›PMID 32071504›Full record

ArticleIndian journal of clinical biochemistry : IJCB2020

ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer.

Maryam Tabatabian, Hamzeh Mesrian Tanha, Hossein Tabatabaeian, Samira Sadeghi, Kamran Ghaedi, Parisa Mohamadynejad

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Maryam TabatabianDepartment of Biology, Faculty of Basic Science, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Hamzeh Mesrian Tanha2Cellular and Molecular Biology Division, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, 81746-73441 Iran.
Hossein Tabatabaeian3Division of Genetics, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
Samira Sadeghi3Division of Genetics, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
Kamran Ghaedi2Cellular and Molecular Biology Division, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, 81746-73441 Iran.ORCID 0000-0002-9790-5644
Parisa MohamadynejadDepartment of Biology, Faculty of Basic Science, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Islamic Azad University of Shahrekord · IRUniversity of Isfahan · IRAgency for Science, Technology and Research · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A genetic variant may alter a gene expression level and as a result be associated with pathological characteristics in breast cancer. In this research, the frequency and association of the ErbB4 3'-untranslated region (3'-UTR) variant, rs12471583 (c.*3622A>G) was studied in an Iranian breast cancer patients.

Indexed as

Estrogen receptorFunctional SNPHER4Progesterone receptorStage IV

Identifiers

PMID32071504
PMCPMC6995472
OpenAlexW2893882653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.